News - Bristol-Myers Squibb


Current filters:

Bristol-Myers Squibb

Popular Filters

70 to 94 of 222 results

Bristol-Myers' data on Yervoy and nivolumab causes a stir


Release of abstracts of presentations to be made at the forthcoming49th Annual Meeting of the American…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearchYervoy

IQWiG re-assessments come up with same view for saxagliptin and different for crizotinib


Under the rules of the German Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute…

AstraZenecaBristol-Myers SquibbcrizotinibDiabetesEuropeKomboglyzeOncologyOnglyzaPfizerPharmaceuticalPricingRegulationsaxagliptinXalkori

Positive results from sub-analysis of Eliquis ARISTOTLE trial


US drug major Bristol-Myers Squibb (NYSE: BMY) and partner Pfizer (NYSE: PFE) reported results from a…

Bristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalResearch

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx


US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Bristol-Myers 1st-qtr sales and EPS plunge, missing analysts' forecasts


US drug major Bristol-Myers Squibb (NYSE: BMY) released first-quarter 2013 financial results, showing…

Bristol-Myers SquibbFinancialPharmaceutical

UK's NICE gives final guidance on Esbriet, Orencia and Xolair


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon


US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Santaris Pharma in multi-million dollar deal with Bristol-Myers for RNA-targeted medicines


Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says it has entered into…

BiotechnologyBristol-Myers SquibbLicensingPharmaceuticalResearchSantaris Pharma

Bristol-Myers pumps about $250 million into biologics facility expansion


Just a few days after announcing the closure of its biotech subsidiary Amylin facility in California…

BiotechnologyBristol-Myers SquibbFinancialPharmaceuticalProductionResearch

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress


Swedish infectious disease drug developer Medivir AB (OMX: MVIR) and US partner Johnson & Johnson (NYSE:…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirMerck & CoMK-5172PharmaceuticalResearchsimeprevirVaniprevirVictrelis

Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head


US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has entered into a non-exclusive agreement with pharma…

Anti-viralsBristol-Myers SquibbdaclatasvirManagementPharmaceuticalResearchVertexVX-135

Germany's IQWiG finds considerable added benefit for Bristol-Myers/Pfizer's Eliquis


In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

Briefs: Pfizer $142 million fine upheld; Bristol-Myers shuts Amylin facility


The US Court of Appeals in Boston has upheld a $142.1 million damage award to Kaiser Foundation Health…

AmylinBristol-Myers SquibbLegalManagementMarkets & MarketingNeurontinNorth AmericaPfizerPharmaceutical

Xarelto and Eliquis set to displace current therapies in DVT/PE


Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

Germany's IQWiG finds no added benefit for AstraZeneca and Bristol-Myers' Forxiga


In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Merck KGaA links with Bristol-Myers for Glucophage promotion in China


German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

NICE green light for earlier use of Bristol-Myers' Orencia


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) now recommends…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalRegulation

Germany's IQWiG finds no added benefit for Komboglyze or for Pixuvri


In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

AstraZenecaBiotechnologyBristol-Myers SquibbCell TherapeuticsDiabetesEuropeKomboglyzemetforminOncologyPharmaceuticalPixuvriPricingRegulationsaxagliptin

Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds


People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those…

Bristol-Myers SquibbByettaDiabetesJanuviaMerck & CoPharmaceuticalResearch

70 to 94 of 222 results

Back to top